These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37909622)

  • 21. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
    Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model.
    Bakırcı Ş; Sağsöz N; Devrim T; Şahin Y; Bulanık M; Gözüyukarı H
    Gynecol Endocrinol; 2022 Dec; 38(12):1093-1096. PubMed ID: 36579847
    [No Abstract]   [Full Text] [Related]  

  • 23. Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome.
    Turktekin N; Karakus C; Ozyurt R
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1248-1254. PubMed ID: 35253181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
    Luo J; Qi Q; Chen Y; Wang Y; Xie Q
    Reprod Biomed Online; 2021 Feb; 42(2):291-300. PubMed ID: 33249057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
    Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
    Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
    Shrem G; Steiner N; Balayla J; Volodarsky-Perel A; Tannus S; Son WY; Dahan MH
    Reprod Biomed Online; 2019 Sep; 39(3):433-438. PubMed ID: 31320288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
    Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
    Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Carizza C; Abdelmassih V; Abdelmassih S; Ravizzini P; Salgueiro L; Salgueiro PT; Jine LT; Nagy P; Abdelmassih R
    Reprod Biomed Online; 2008 Dec; 17(6):751-5. PubMed ID: 19079957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model.
    Jiang S; Li W; Zhao X; Chen L; Kuang Y
    Drug Des Devel Ther; 2022; 16():397-411. PubMed ID: 35221672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome.
    Pascuali N; Scotti L; Oubiña G; de Zúñiga I; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2020 Aug; 26(8):585-600. PubMed ID: 32467982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad S; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Esinler I; Bozdag G; Karakocsokmensuer L
    Arch Gynecol Obstet; 2013 Nov; 288(5):1159-63. PubMed ID: 23677417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study.
    Fouda UM; Elshaer HS; Youssef GG; Hanafy A; Mehrem WM; Youssef MA; Farouk M; Nabil H
    J Obstet Gynaecol; 2022 Jan; 42(1):122-126. PubMed ID: 34270379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
    J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.